Ensifentrine

GOLD 2025 updates COPD management, removing ICS/LABA from initial therapy and adding ensifentrine for symptom relief and dupilumab for high eosinophil count patients, emphasizing tailored treatment based on symptoms or exacerbations.

Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.

Verona Pharma, a biopharmaceutical company, focuses on respiratory disease treatments, with ensifentrine in Phase 3 trials for COPD, asthma, and cystic fibrosis. Caligan Partners LP, an activist investor, sees potential in Verona's ensifentrine, predicting significant revenue growth and possible indication expansion for non-cystic fibrosis bronchiectasis.

Verona Pharma (VRNA) reported Q3 2024 earnings, with $5.6 million in net sales for its COPD treatment Ohtuvayre. The launch saw over 5,000 prescriptions filled by 2,200 healthcare professionals. The company is conducting two Phase 2 trials and reported a $43 million net loss due to increased R&D and SG&A expenses. Verona Pharma's cash position is $336 million, and management is optimistic about future growth.

Verona Pharma reports Q3 net sales of $5.6 million for Ohtuvayre™ (ensifentrine), with October sales exceeding Q3. Over 2,200 unique prescribers and 5,000 prescriptions filled for COPD treatment. Two Phase 2 programs initiated, and a conference call scheduled for November 4, 2024.

Verona Pharma reports Q3 net sales of $5.6 million for Ohtuvayre (ensifentrine), with October sales exceeding Q3. Over 2,200 prescribers and 5,000 prescriptions filled for COPD treatment. Two Phase 2 programs initiated, and a conference call scheduled for November 4, 2024.

Verona Pharma will report Q3 2024 financial results on Nov 4, hosting a conference call at 9:00 a.m. EDT / 2:00 p.m. GMT. The call can be joined via phone or webcast on the company's website, with a replay available for 90 days.

FDA approved ensifentrine (Ohtuvayre) for COPD treatment on June 26, 2024, based on two phase 3 trials (ENHANCE-1, NCT04535986; ENHANCE-2, NCT04542057) showing significant improvements in FEV1 AUC0-12h. Ensifentrine inhibits PDE-3 and PDE-4, reducing inflammation and relaxing airway smooth muscle. Safety concerns include psychiatric adverse reactions and paradoxical bronchospasm. Dosed twice daily via oral inhalation, ensifentrine's high cost ($35,400/year) raises affordability issues.

Ohtuvayre (ensifentrine) safely and effectively improves COPD symptoms, lung function, and quality of life regardless of disease severity, smoking history, or chronic bronchitis, according to post-hoc analyses of Phase 3 ENHANCE trials.